Meropenem Qilu (Meropenem)

Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This disruption leads to loss of cell wall integrity and bacterial cell death, providing a broad‑spectrum, bactericidal effect against many Gram‑positive, Gram‑negative and anaerobic pathogens.

The specific dose and infusion rate of Meropenem Qilu are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local antimicrobial guidelines. Healthcare professionals adjust the regimen to achieve optimal therapeutic levels while minimizing toxicity.

Safety data for Meropenem in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case individually and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the Meropenem Qilu product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Meropenem shares a similar spectrum with other carbapenems such as imipenem‑cilastatin and ertapenem, but it offers a broader activity against Pseudomonas aeruginosa and better stability against many β‑lactamases. Choice among carbapenems depends on local resistance patterns, dosing convenience, and patient‑specific factors.

Meropenem Qilu must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature for a short period during preparation, it should be used promptly.

Meropenem Qilu is given by intravenous infusion, typically over 15‑30 minutes. The infusion rate and total daily dose are set by the treating physician based on infection severity, renal function, and microbiological data. Administration should follow aseptic technique in a clinical setting.

Serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and significant nephrotoxicity. Prompt recognition and discontinuation are essential if these events occur.

Patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics should avoid the drug. Caution is also advised for individuals with a history of seizures, severe renal or hepatic impairment, and those receiving valproic acid, unless the prescriber determines the benefits outweigh the risks.